1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6144A88B477CE7C826525852800267813
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/144A88B477CE7C826525852800267813?OpenDocument
18
19OpenDocument
2018.97.14.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

Document Excerpt: Maximizing the Impact of Medical Affairs in Oncology Product Launches: Role and Activities

DB Image

Excerpt in Cart

ID: MD-705


Features:

17 Info Graphics

15 Data Graphics

350+ Metrics


Pages/Slides: 4


Published: Pre-2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5605 "Maximizing the Impact of Medical Affairs in Oncology Product Launches: Role and Activities”.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Chemical; Health Care; Diagnostic; Medical Device


Companies Profiled:
AbbVie; Alkermes; AstraZeneca; Boehringer Ingelheim; Celgene; Cipla; Clovis Oncology; Crescendo Bioscience; Curis; Daiichi Sankyo; Eisai; Exelixis ; GRAIL; Merck; Merck KGaA; Novartis; Roche; Sandoz; Sanofi Genzyme; Servier; Shire; Taiho Oncology; Takeda Pharmaceuticals; Torrent Pharmaceuticals Ltd.; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.